HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $10
HC Wainwright & Co. analyst Douglas Tsao maintains Radius Health (NASDAQ:RDUS) with a Neutral and lowers the price target from $23 to $10.
Mid-Afternoon Market Update: Nasdaq Rises 70 Points; Stitch Fix Shares Slide
Toward the end of trading Wednesday, the Dow traded down 0.08% to 35,692.63 while the NASDAQ rose 0.45% to 15,757.04. The S&P also rose, gaining 0.12% to 4,692.41.
Radius Health Reveals Detailed Elacestrant Data From Late-Stage Breast Cancer Trial
The Menarini Group and Radius Health Inc (NASDAQ: RDUS) have
35 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options to maximize shareholder value, including potential merger or acquisition.
Radius Health Highlights EMERALD Trial Results For Elacestrant Presented At San Antonio Breast Cancer Symposium: Trial Met Both Primary Endpoints
Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall
Radius Announces wearABLe Trial Evaluating Abaloparatide Transdermal System Did Not Meet Primary Endpoint
The wearABLe study did not demonstrate non-inferiority of abalo-TDS to TYMLOS®
Lumbar spine BMD at 12 months vs. baseline for abalo-TDS was +7.1% vs. TYMLOS +10.9%
Both abalo-TDS and TYMLOS
What 5 Analyst Ratings Have To Say About Radius Health
Over the past 3 months, 5 analysts have published their opinion on Radius Health (NASDAQ:RDUS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $30
SVB Leerink analyst Geoffrey Porges maintains Radius Health (NASDAQ:RDUS) with a Market Perform and raises the price target from $29 to $30.
SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $30
SVB Leerink analyst Geoffrey Porges maintains Radius Health (NASDAQ:RDUS) with a Market Perform and raises the price target from $29 to $30.